Press release 📈 Stocks 🌍 United States

Eli Lilly to Acquire Calytrix Bio in Deal Valued at Up to $1.5 Billion

Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion, securing a preclinical antibody program aimed at treating mutant calreticulin-driven blood cancers.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: LLY → 2/10 (60% confidence).

📊 Affected Assets (1)

LLY
Neutral 🤖 60%
📅 Short-term 🌍 US · Explicit

Lilly agreed to acquire Calytrix Bio, with shareholders receiving up to $1.5 billion in cash including upfront and milestone payments. The deal broadens Lilly's myeloproliferative neoplasm pipeline with a preclinical antibody for mCALR-driven essential thrombocythemia and myelofibrosis. For a company of Lilly's size this outlay is small and the asset is still preclinical, so no material price effect is expected in the near term.

Catalysts
  • • Definitive agreement announced November 16, 2026 for Lilly to acquire Calytrix Bio
  • • Up to $1.5 billion in cash including upfront and milestone payments
Risk Factors
  • • Lead asset is preclinical with clinical and regulatory milestones still to be met
  • • Payments contingent on achievement of clinical and regulatory milestones

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Eli Lilly will pay up to $1.5 billion in cash, including upfront and milestone-based payments, to acquire Calytrix Bio.
  • The acquisition centers on a preclinical biparatopic antibody designed to treat mCALR-driven essential thrombocythemia and myelofibrosis.
  • Calytrix Bio was founded in 2025 and backed by investors including J.P. Morgan Life Sciences Private Capital, Westlake BioPartners, and Avoro Ventures.

📝 Executive Summary

Eli Lilly and Company announced a definitive agreement on November 16, 2026, to acquire Calytrix Bio. The deal, valued at up to $1.5 billion in cash, includes an upfront payment and additional funds tied to clinical and regulatory milestones. This acquisition adds a preclinical biparatopic antibody targeting mutant calreticulin-driven essential thrombocythemia and myelofibrosis to Lilly's oncology pipeline.

❓ FAQ

How much is Lilly paying for Calytrix Bio?

Calytrix shareholders could receive up to $1.5 billion in cash, including an upfront payment plus additional payments if certain clinical and regulatory milestones are met.

What does Lilly get from the deal?

A potentially best-in-class preclinical biparatopic antibody targeting mutant calreticulin-driven essential thrombocythemia and myelofibrosis, which broadens Lilly's presence in blood cancers.